Aroa Biosurgery’s Myriad bioscaffold shows low infection rates in a 411‑patient study, bolstering its case for wider use in complex soft tissue reconstruction
Executive summary: A peer‑reviewed study of 411 patients using Aroa Biosurgery’s Myriad™ bioscaffold in complex soft tissue reconstruction reported low infection rates. Low infection rates improve patient outcomes and could reduce healthcare costs, supporting broader clinical and reimbursement acceptance of the bioscaffold.
Who is involved: Aroa Biosurgery Limited (ASX: ARX), investigators of the MASTRR Registry, and patients undergoing soft tissue reconstruction.
Likely next: Aroa may pursue additional regulatory submissions and seek wider hospital uptake based on the interim results.
The interim MASTRR Registry analysis, described as the largest prospective bioscaffold study in inpatient soft tissue reconstruction to date, reports low infection rates for Myriad™ across 411 patients. The findings suggest the bioscaffold may reduce postoperative complications compared with standard grafts. While the data are interim, they provide clinically meaningful evidence that could influence adoption decisions by surgeons and purchasing committees.
Timeline
- — Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction (PR Newswire)
Analysis — what this means
Sectors affected
- Medical device bioscaffolds
- Soft tissue reconstruction
- Regenerative medicine